Clinical trials: sponsored by Sanofi
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Neoplasm Malignant
Phase 1 Safety Testing of SAR405838
Primary Objectives: To determine safety and the maximum tolerated dose (MTD) of SAR405838 through the characterization of dose-limiting toxicities (DLTs).
- Trial name
- NCT01636479
- Testing
- SAR405838
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 77 people
- Sponsor
- Sanofi
Intermittent Claudication
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
The primary objective is to investigate in patients suffering from intermittent claudication due to Fontaine stage II Peripheral Arterial Disease (PAD) whether a 26-week treatment by HMR1766 on top of clopidogrel may result in an…
- Trial name
- ACCELA (NCT00443287)
- Testing
- ataciguat (HMR1766), cilostazol
- Where
- 7 sites in United States, Austria and 5 more
- Volunteers
- 553 people
- Sponsor
- Sanofi
Thyroid Cancer
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
- Trial name
- NCT00098345
- Testing
- ZD6474 (vandetanib)
- Where
- 6 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Dyslipidemia
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Primary Objective: To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at…
- Trial name
- NCT02642159
- Testing
- Alirocumab, Statins, Ezetimibe
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00256113
- Testing
- Saredutant succinate (SR48968C)
- Where
- 8 sites in Canada, Chile and 6 more
- Volunteers
- 467 people
- Sponsor
- Sanofi
Colorectal Cancer Metastatic
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Primary Objective: To provide metastatic colorectal cancer participants with access to aflibercept and to document the overall safety in these participants Secondary Objective: To document the Health-Related Quality of Life of…
- Trial name
- NCT01571284
- Testing
- AFLIBERCEPT AVE0005, FOLFIRI
- Where
- 179 sites in United States, Belgium and 21 more
- Volunteers
- 781 people
- Sponsor
- Sanofi
Cholera
A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic
The aim of the study is to generate safety and immunogenicity data with Shanchol in The Philippines Objectives: To describe the safety after each dose of Shanchol vaccine.
- Trial name
- NCT02434822
- Testing
- Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
- Where
- Dominican Republic
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cholera
A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines
The aim of the study is to generate safety and immunogenicity data with Oral Cholera Vaccine (Shanchol™) in The Philippines Objectives: To describe the safety after each dose of Shanchol vaccine.
- Trial name
- NCT01949675
- Testing
- Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
- Where
- 2 sites in Philippines
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B
Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age
Primary Objective: To describe the persistence of Hep B antibodies (Ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either Hexaxim®/Hexyon®/Hexacima® or Infanrix® hexa at 2, 4 and 6…
- Trial name
- NCT02610348
- Testing
- DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines, DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
- Where
- 2 sites in Thailand
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine
Primary objective: Immunogenicity To demonstrate that the influenza vaccine administered by intradermal route at least as immunogenic as the adjuvanted influenza vaccine administered by intramuscular route at the same dosage in…
- Trial name
- NCT00554333
- Testing
- Flu-ID 15μg, Inactivated adjuvanted Influenza Vaccine
- Where
- 8 sites in Belgium, France
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Head and Neck Neoplasms
Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial
The Primary Objective is to evaluate the progression-free survival after treatment with docetaxel plus cisplatin plus 5-Fluorouracil (5-FU) (DCF) in comparison with cisplatin plus 5-FU (CF) in patient with locally advanced…
- Trial name
- NCT00995293
- Testing
- DOCETAXEL, CISPLATIN, 5-FLUOROURACIL
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Sanofi
Dengue, Dengue Fever
Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects
To evaluate effect of previous flavivirus exposure on the safety and immunogenicity of the ChimeriVax™ dengue tetravalent vaccine Primary Objectives: To describe the safety of one injection of ChimeriVax™ dengue tetravalent…
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
- Trial name
- NCT00730288
- Testing
- Chimeric dengue serotype (1, 2, 3, 4)
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes
Primary Objective: To compare Insuman Implantable 400 IU/ml versus Insuplant 400 IU/ml with respect to the pump refill accuracy during a 4 refill cycle period (i.e.
- Trial name
- NCT01194882
- Testing
- HUMAN INSULIN (BIOSYNTHETIC), Insuplant
- Where
- 17 sites in Belgium, France and 2 more
- Volunteers
- 479 people
- Sponsor
- Sanofi
Influenza
A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older
The aim of the study is to assess the safety and immunogenicity of two formulations of the high-dose quadrivalent influenza vaccine compared to the licensed high-dose trivalent influenza vaccine control in healthy elderly…
- Trial name
- NCT02553343
- Testing
- High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine
- Where
- 9 sites in United States
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use
The aim of this study is to generate data on immunogenicity and safety of Purified Vero Rabies Vaccine - Serum Free (VRVg) in comparison with Imovax® Rabies in order to support the registration of VRVg in the USA.
- Trial name
- NCT01784874
- Testing
- Purified Vero Rabies Vaccine (VRVg) - Serum Free, Imovax® Rabies: inactivated rabies vaccine
- Where
- 6 sites in United States
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal Infection
Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers
This study is aimed at studying quadrivalent meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) formulations in Toddlers.
- Trial name
- NCT00631995
- Testing
- Meningococcal Polysaccharide Tetanus Protein Conjugate, Meningococcal polysaccharide group C conjugated
- Where
- 5 sites in Australia
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Breast Cancer Metastatic
Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer
Primary Objectives: To assess the safety for each cohort of patients on a fixed-dose combination pill of capecitabine and cyclophosphamide administered at flat dose and with metronomic schedule (defined as continuous daily…
- Trial name
- METRO-ABC (NCT02664103)
- Testing
- Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
- Where
- 5 sites in India
- Volunteers
- 2 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
Primary Objective: -To demonstrate that sarilumab added to methotrexate (MTX) reduce signs and symptoms of rheumatoid arthritis (RA) in Japanese RA participants with an inadequate response to MTX.
- Trial name
- NCT02293902
- Testing
- Sarilumab SAR153191 (REGN88), Methotrexate, Folic acid
- Where
- 96 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
Primary Objective: To document the long-term safety of sarilumab added to non-methotrexate (non-MTX) disease-modifying antirheumatic drugs (DMARDs) or as monotherapy.
- Trial name
- NCT02373202
- Testing
- Sarilumab, Sulfasalazine, Leflunomide
- Where
- 40 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.